Menu

Natera, Inc. NTRA

Full chart Compare
Set alert

Price alert · NTRA

All alert types
319.82 USD +7.84 (+2.51%)

At closeNov 12, 2026, 6:24 AM EST

319.00 -0.82 -0.26%

Pre-market · Nov 12, 6:24 AM ET

314.45 Day range 325.35
181.00 52-week range 437.41
YTD
+39.60%
1 year
+52.66%
Market cap
46.38B
Revenue (ttm)
2.91B
Profit margin
-5.66%
EPS (ttm)
-1.12
Shares out
145.00M
Forward P/E
-946.21
YTD return
+39.60%
1-year return
+52.66%
Volume
1.75M
Avg volume
1.71M
Open
322.13
Previous close
311.98
Day's range
314.45 – 325.35
52-week range
181.00 – 437.41
Beta
1.51
Analysts
Strong Buy
Price target
410.02 (+28.2%)
Earnings date
Feb 25, 2027

5D -48.18 (-13.09%)

300320340360ThuFriMonTueWed319.82

Key statistics

Enterprise value
44.38B
PEG ratio
0.00
Price / sales
15.94
Price / book
24.69
Dividend yield
0.00%
Payout ratio
0.00%
Revenue growth
34.10%
Free cash flow
84.54M
Total cash
1.10B
Total debt
238.84M
Return on equity
-10.55%
Short % of float
4.33%
50-day average
379.93
200-day average
270.09

Financials — quick view

All financials
NTRA Revenue — quarterly 793.98M
2022-Q4 20222023-Q1 20232023-Q2 20232023-Q3 20232023-Q4 20232024-Q1 20242024-Q2 20242024-Q3 20242024-Q4 20242025-Q1 20252025-Q2 20252025-Q3 20252025-Q4 20252026-Q1 20262026-Q2 20262026-Q3 2026
NTRA Net income — quarterly -59.91M
2022-Q4 20222023-Q1 20232023-Q2 20232023-Q3 20232023-Q4 20232024-Q1 20242024-Q2 20242024-Q3 20242024-Q4 20242025-Q1 20252025-Q2 20252025-Q3 20252025-Q4 20252026-Q1 20262026-Q2 20262026-Q3 2026
NTRA EPS — quarterly -0.42
2022-Q4 20222023-Q1 20232023-Q2 20232023-Q3 20232023-Q4 20232024-Q1 20242024-Q2 20242024-Q3 20242024-Q4 20242025-Q1 20252025-Q2 20252025-Q3 20252025-Q4 20252026-Q1 20262026-Q2 20262026-Q3 2026

Earnings

NTRA recent earnings
Report dateQuarter endingEPS estimateEPS reportedSurpriseSurprise %
Feb 25, 2027Dec 30, 2026-0.14439———
Nov 5, 2026Sep 30, 2026-0.28103-0.42-0.14-49.45%
Aug 6, 2026Jun 30, 2026-0.49394-0.47+0.02+4.85%
May 7, 2026Mar 31, 2026-0.54222-0.56-0.02-3.28%
Feb 26, 2026Dec 31, 2025-0.512070.35+0.86+168.35%
Nov 6, 2025Sep 30, 2025-0.38569-0.64-0.25-65.94%

Upgrades / downgrades

NTRA analyst upgrades and downgrades
DateFirmActionFromTo
Nov 9, 2026BairdmainOutperformOutperform
Nov 6, 2026JP MorganmainOverweightOverweight
Nov 6, 2026Evercore ISI GroupmainOutperformOutperform
Oct 27, 2026BTIGmainBuyBuy
Oct 19, 2026Canaccord GenuitymainBuyBuy
Oct 14, 2026JP MorganmainOverweightOverweight

About Natera, Inc.

Natera, Inc., a diagnostics company, engages in the development and commercialization of molecular testing services worldwide. It offers Signatera, a personalized ctDNA blood test for MRD assessment, early recurrence monitoring, and evaluation of treatment response in patients previously diagnosed with cancer; Latitude, a blood-based MRD test for colorectal cancer; Altera, a tissue based comprehensive genomic profiling test; and Empower, a hereditary cancer screening test. The company also provides Panorama, a non-invasive prenatal test; Horizon, a carrier screening test; Fetal Focus, a single-gene NIPT, or sgNIPT, that screens for 21 single-gene inherited conditions; and Vistara, a single-gene NIPT, which screens for 25 single-gene conditions. In addition, it offers Anora, which tests and analyzes miscarriage tissue from women who have experienced one or more pregnancy losses; Empower, a hereditary cancer screening test; Prospera, a test to assess active rejection in patients who have undergone solid organ transplantation; Renasight, a kidney gene panel test; and Constellation software, a cloud-based distribution model. Further, the company provides NateraCore, a platform to support the patient and provider experience; phlebotomy services; and EMR integration services. The company serves independent laboratories, national and regional reference laboratories, medical centers and physician practices for its screening tests, research laboratories, and pharmaceutical companies through its direct sales force and laboratory distribution partners, as well as Constellation licensees under its cloud-based distribution model. It has a partnership agreement with BGI Genomics Co., Ltd. to develop, manufacture, and commercialize NGS-based genetic testing assays for clinical and commercial use. The company was formerly known as Gene Security Network, LLC and changed its name to Natera, Inc. in January 2012. Natera, Inc. was founded in 2003 and is headquartered in Austin, Texas.

Sector
Healthcare
Industry
Diagnostics & Research
Country
United States
Website
natera.com

News

Your note

Sign in to keep a note on NTRA — it syncs with the Stock Master app.

Insider holders

NTRA insider holders
InsiderRelationLatest transactionDateShares held
BAYNES ROY DDirectorStock Award(Grant)Jun 25, 202620,158
BOTHA ROELOF FREDERICKDirectorStock Award(Grant)Jun 25, 20261,080,780
BROPHY MICHAEL BURKESChief Financial OfficerSaleNov 2, 202645,779
CHAPMAN STEVEN LEONARDChief Executive OfficerSaleNov 1, 202687,431
FESKO JOHNPresidentSaleNov 1, 2026195,276
HEALY JAMES IDirectorStock Award(Grant)Apr 24, 20251,596,540

Institution ownership

NTRA institution ownership
Holder% heldSharesValueReported
FMR, LLC9.43%13,680,3084.38BSep 29, 2026
JPMORGAN CHASE & CO8.87%12,865,3464.11BJun 29, 2026
Blackrock Inc.7.53%10,914,6083.49BJun 29, 2026
Price (T.Rowe) Associates Inc6.22%9,021,8952.89BJun 29, 2026
Vanguard Capital Management LLC4.30%6,228,2161.99BJun 29, 2026
Vanguard Portfolio Management LLC3.99%5,782,6401.85BJun 29, 2026

Fund ownership

NTRA fund ownership
Holder% heldSharesValueReported
JPMorgan Trust II-JPMorgan Large Cap Growth Fund3.83%5,550,9401.78BJun 29, 2026
VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund2.98%4,320,3511.38BJun 29, 2026
VANGUARD INDEX FUNDS-Vanguard Small-Cap Index Fund2.15%3,119,416997.65MJun 29, 2026
Fidelity Contrafund1.88%2,724,482871.34MSep 29, 2026
VANGUARD INDEX FUNDS-Vanguard Small-Cap Growth Index Fund1.24%1,799,359575.47MJun 29, 2026
VANGUARD INDEX FUNDS-Vanguard Extended Market Index Fund1.13%1,642,271525.23MJun 29, 2026